Chandler Andrew, Bartelstein Meredith K, Fujiwara Tomohiro, Antonescu Cristina R, Healey John H, Vaynrub Max
Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY, 10065, USA.
Touro College of Osteopathic Medicine, New York, NY, USA.
BMC Musculoskelet Disord. 2021 Apr 1;22(1):320. doi: 10.1186/s12891-021-04182-z.
Giant cell tumor of bone is a benign, locally aggressive neoplasm. Surgical resection is the preferred treatment method. However, for cases in which resection poses an increased risk to the patient, denosumab (anti-RANKL monoclonal antibody) is considered. Secukinumab is an anti-IL-17 antibody that is used in psoriatic arthritis to reduce bone resorption and articular damage.
One case of giant cell tumor of bone (GCTB) in a patient treated with secukinumab for psoriatic arthritis demonstrated findings significant for intra-lesional calcifications. Histologic examination showed ossification, new bone formation, and remodeling. A paucity of osteoclast type giant cells was noted. Real-time quantitative polymerase-chain-reaction (qRT-PCR) analysis revealed decreased osteoclast function compared to treatment-naive GCTB.
Secukinumab may play a role in bone remodeling for GCTB. Radiologists, surgeons, and pathologists should be aware of this interaction, which can cause lesional ossification. Further research is required to define the therapeutic potential of this drug for GCTB and osteolytic disease.
骨巨细胞瘤是一种良性、具有局部侵袭性的肿瘤。手术切除是首选的治疗方法。然而，对于手术切除会增加患者风险的病例，则考虑使用地诺单抗（抗RANKL单克隆抗体）。司库奇尤单抗是一种抗IL-17抗体，用于治疗银屑病关节炎以减少骨吸收和关节损伤。
一名因银屑病关节炎接受司库奇尤单抗治疗的患者发生骨巨细胞瘤（GCTB），病变内出现明显钙化。组织学检查显示有骨化、新骨形成和重塑。破骨细胞型巨细胞数量较少。实时定量聚合酶链反应（qRT-PCR）分析显示，与未经治疗的GCTB相比，破骨细胞功能下降。
司库奇尤单抗可能在GCTB的骨重塑中发挥作用。放射科医生、外科医生和病理学家应了解这种可导致病变骨化的相互作用。需要进一步研究来确定该药物对GCTB和溶骨性疾病的治疗潜力。
